Medpace Holdings, Inc. (NASDAQ:MEDP) Major Shareholder Medpace Investors, Llc Sells 33,000 Shares

Medpace Holdings, Inc. (NASDAQ:MEDP) major shareholder Medpace Investors, Llc sold 33,000 shares of the stock in a transaction dated Wednesday, November 15th. The shares were sold at an average price of $283.42, for a total transaction of $9,352,860.00. Following the sale, the insider now directly owns 5,856,947 shares in the company, valued at $1,659,975,918.74. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Medpace Investors, Llc also recently made the following trade(s):

• On Wednesday, September 20th, Medpace Investors, Llc sold 65,653 shares of Medpace stock. The stock was sold at an average price of $255.48, for a total transaction of $16,773,028.44.
• On Monday, September 18th, Medpace Investors, Llc sold 53,385 shares of Medpace stock. The shares were sold at an average price of $274.76, for a total transaction of $14,668,062.60.

Medpace Trading Down 0.3 %

NASDAQ:MEDP opened at $281.47 on Friday. The company has a market cap of $8.64 billion, a PE ratio of 32.96 and a beta of 1.37. The company has a 50 day simple moving average of $255.75 and a two-hundred day simple moving average of $242.22. Medpace Holdings, Inc. has a 12 month low of $167.00 and a 12 month high of $287.00.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, October 23rd. The company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.05 by $0.17. Medpace had a return on equity of 68.48% and a net margin of 15.33%. The company had revenue of $492.50 million during the quarter, compared to analyst estimates of $475.79 million. During the same quarter in the previous year, the company posted $2.05 earnings per share. Medpace’s revenue was up 28.3% compared to the same quarter last year. Research analysts forecast that Medpace Holdings, Inc. will post 8.65 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on MEDP. StockNews.com started coverage on Medpace in a research report on Thursday, October 5th. They issued a “hold” rating on the stock. Guggenheim upped their price target on Medpace from $252.00 to $273.00 and gave the company a “buy” rating in a report on Tuesday, July 25th. Robert W. Baird upgraded Medpace from a “neutral” rating to an “outperform” rating and lifted their price objective for the stock from $270.00 to $289.00 in a report on Tuesday, October 24th. Finally, UBS Group boosted their target price on Medpace from $215.00 to $270.00 in a research report on Wednesday, July 26th.

Hedge Funds Weigh In On Medpace

Several institutional investors have recently made changes to their positions in the business. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Medpace during the second quarter valued at approximately $42,000. LSV Asset Management raised its holdings in Medpace by 5,285.2% in the 1st quarter. LSV Asset Management now owns 54,229 shares of the company’s stock worth $10,198,000 after purchasing an additional 53,222 shares during the period. Handelsbanken Fonder AB raised its holdings in Medpace by 46.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 4,700 shares of the company’s stock worth $1,129,000 after purchasing an additional 1,500 shares during the period. Icon Wealth Partners LLC purchased a new position in Medpace during the first quarter valued at $338,000. Finally, Aviva PLC grew its holdings in Medpace by 63.0% during the first quarter. Aviva PLC now owns 7,828 shares of the company’s stock valued at $1,472,000 after purchasing an additional 3,027 shares during the period. Institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.